Potential Applications of Image-guided Radiotherapy for Radiation Dose Escalation in Patients with Early Stage High-risk Prostate Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2015 Feb 21

PMID 25699239

Citations 5

Authors

Nam P Nguyen

Rick Davis

Satya R Bose

Suresh Dutta

Vincent Vinh-Hung

Alexander Chi

Juan Godinez

Anand Desai

William Woods

Gabor Altdorfer

Mark DAndrea

Ulf Karlsson

Richard A Vo

Thomas Sroka

Affiliations

Soon will be listed here.

Abstract

Patients with early stage high-risk prostate cancer (prostate specific antigen > 20, Gleason score > 7) are at high risk of recurrence following prostate cancer irradiation. Radiation dose escalation to the prostate may improve biochemical-free survival for these patients. However, high rectal and bladder dose with conventional three-dimensional conformal radiotherapy may lead to excessive gastrointestinal and genitourinary toxicity. Image-guided radiotherapy (IGRT), by virtue of combining the steep dose gradient of intensity-modulated radiotherapy and daily pretreatment imaging, may allow for radiation dose escalation and decreased treatment morbidity. Reduced treatment time is feasible with hypo-fractionated IGRT and it may improve patient quality of life.

Citing Articles

Development and validation of a prognostic nomogram for neuroendocrine prostate cancer, based on the SEER database.

Chen S, Xiong K, Shi J, Yao S, Wang G, Qian K Front Surg. 2023; 10:1110040.

PMID: 36969760 PMC: 10036588. DOI: 10.3389/fsurg.2023.1110040.

Targeted Chemoradiotherapy of Prostate Cancer Using Gold Nanoclusters with Protease Activatable Monomethyl Auristatin E.

Luo D, Wang X, Walker E, Springer S, Ramamurthy G, Burda C ACS Appl Mater Interfaces. 2022; 14(13):14916-14927.

PMID: 35316026 PMC: 9153066. DOI: 10.1021/acsami.1c23780.

Rectal dose to prostate cancer patients treated with proton therapy with or without rectal spacer.

Chung H, Polf J, Badiyan S, Biagioli M, Fernandez D, Latifi K J Appl Clin Med Phys. 2017; 18(1):32-39.

PMID: 28291917 PMC: 5689902. DOI: 10.1002/acm2.12001.

Multiparametric magnetic resonance imaging-transrectal ultrasound fusion-assisted biopsy for the diagnosis of local recurrence after radical prostatectomy.

Muller B, Kaushal A, Sankineni S, Lita E, Hoang A, George A Urol Oncol. 2015; 33(10):425.e1-425.e6.

PMID: 26259666 PMC: 5703071. DOI: 10.1016/j.urolonc.2015.05.021.

The future of nanosized radiation enhancers.

Pottier A, Borghi E, Levy L Br J Radiol. 2015; 88(1054):20150171.

PMID: 26248871 PMC: 4730967. DOI: 10.1259/bjr.20150171.

References

Katz A, Santoro M, Diblasio F, Ashley R . Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years. Radiat Oncol. 2013; 8:118. PMC: 3674983. DOI: 10.1186/1748-717X-8-118. View

Antolak J, Rosen I, Childress C, Zagars G, Pollack A . Prostate target volume variations during a course of radiotherapy. Int J Radiat Oncol Biol Phys. 1998; 42(3):661-72. DOI: 10.1016/s0360-3016(98)00248-x. View

Lee Y, Son S, Yoon S, Yu M, Choi B, Kim Y . Stereotactic body radiotherapy for prostate cancer: a preliminary report. Asia Pac J Clin Oncol. 2012; 10(2):e46-53. DOI: 10.1111/j.1743-7563.2012.01589.x. View

Skarsgard D, Cadman P, El-Gayed A, Pearcey R, Tai P, Pervez N . Planning target volume margins for prostate radiotherapy using daily electronic portal imaging and implanted fiducial markers. Radiat Oncol. 2010; 5:52. PMC: 2896366. DOI: 10.1186/1748-717X-5-52. View

Styles C, Ferris N, Mitchell C, Murphy D, Frydenberg M, Mills J . Multiparametric 3T MRI in the evaluation of intraglandular prostate cancer: correlation with histopathology. J Med Imaging Radiat Oncol. 2014; 58(4):439-48. DOI: 10.1111/1754-9485.12189. View

Zelefsky M, Pei X, Chou J, Schechter M, Kollmeier M, Cox B . Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes. Eur Urol. 2011; 60(6):1133-9. PMC: 4037155. DOI: 10.1016/j.eururo.2011.08.029. View

Dearnaley D, Jovic G, Syndikus I, Khoo V, Cowan R, Graham J . Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2014; 15(4):464-73. DOI: 10.1016/S1470-2045(14)70040-3. View

Tanyi J, He T, Summers P, Mburu R, Kato C, Rhodes S . Assessment of planning target volume margins for intensity-modulated radiotherapy of the prostate gland: role of daily inter- and intrafraction motion. Int J Radiat Oncol Biol Phys. 2010; 78(5):1579-85. DOI: 10.1016/j.ijrobp.2010.02.001. View

Hong S, Eastham J, Fine S . Localization of higher grade tumor foci in potential candidates for active surveillance who opt for radical prostatectomy. Prostate Int. 2014; 1(4):152-7. PMC: 3879052. DOI: 10.12954/PI.13029. View

10.

Zelefsky M, Kollmeier M, Cox B, Fidaleo A, Sperling D, Pei X . Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2012; 84(1):125-9. DOI: 10.1016/j.ijrobp.2011.11.047. View

11.

Norkus D, Karklelyte A, Engels B, Versmessen H, Griskevicius R, De Ridder M . A randomized hypofractionation dose escalation trial for high risk prostate cancer patients: interim analysis of acute toxicity and quality of life in 124 patients. Radiat Oncol. 2013; 8:206. PMC: 3846611. DOI: 10.1186/1748-717X-8-206. View

12.

Bolzicco G, Silvia Favretto M, Satariano N, Scremin E, Tambone C, Tasca A . A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy. BMC Urol. 2013; 13:49. PMC: 4016542. DOI: 10.1186/1471-2490-13-49. View

13.

Anwar M, Westphalen A, Jung A, Noworolski S, Simko J, Kurhanewicz J . Role of endorectal MR imaging and MR spectroscopic imaging in defining treatable intraprostatic tumor foci in prostate cancer: quantitative analysis of imaging contour compared to whole-mount histopathology. Radiother Oncol. 2014; 110(2):303-8. PMC: 3969841. DOI: 10.1016/j.radonc.2013.12.003. View

14.

Kok D, Gill S, Bressel M, Byrne K, Kron T, Fox C . Late toxicity and biochemical control in 554 prostate cancer patients treated with and without dose escalated image guided radiotherapy. Radiother Oncol. 2013; 107(2):140-6. DOI: 10.1016/j.radonc.2013.04.007. View

15.

Alongi F, Fogliata A, Navarria P, Tozzi A, Mancosu P, Lobefalo F . Moderate hypofractionation and simultaneous integrated boost with volumetric modulated arc therapy (RapidArc) for prostate cancer. Report of feasibility and acute toxicity. Strahlenther Onkol. 2012; 188(11):990-6. DOI: 10.1007/s00066-012-0171-7. View

16.

Hoffman K, Voong K, Pugh T, Skinner H, Levy L, Takiar V . Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. Int J Radiat Oncol Biol Phys. 2014; 88(5):1074-84. DOI: 10.1016/j.ijrobp.2014.01.015. View

17.

Yoshida K, Yamazaki H, Takenaka T, Kotsuma T, Yoshida M, Masui K . High-dose-rate interstitial brachytherapy in combination with androgen deprivation therapy for prostate cancer: are high-risk patients good candidates?. Strahlenther Onkol. 2014; 190(11):1015-20. DOI: 10.1007/s00066-014-0675-4. View

18.

Strom T, Hutchinson S, Shrinath K, Cruz A, Figura N, Nethers K . External beam radiation therapy and a low-dose-rate brachytherapy boost without or with androgen deprivation therapy for prostate cancer. Int Braz J Urol. 2014; 40(4):474-83. DOI: 10.1590/S1677-5538.IBJU.2014.04.05. View

19.

Pahlajani N, Ruth K, Buyyounouski M, Chen D, Horwitz E, Hanks G . Radiotherapy doses of 80 Gy and higher are associated with lower mortality in men with Gleason score 8 to 10 prostate cancer. Int J Radiat Oncol Biol Phys. 2011; 82(5):1949-56. PMC: 3827957. DOI: 10.1016/j.ijrobp.2011.04.005. View

20.

Hanley J, Lumley M, Mageras G, Sun J, Zelefsky M, Leibel S . Measurement of patient positioning errors in three-dimensional conformal radiotherapy of the prostate. Int J Radiat Oncol Biol Phys. 1997; 37(2):435-44. DOI: 10.1016/s0360-3016(96)00526-3. View